Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Aslan Pharmaceuticals Ltd (ASLN) and Advaxis (ADXS).
Aslan Pharmaceuticals Ltd (ASLN)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Aslan Pharmaceuticals Ltd, with a price target of $8.50. The company’s shares closed yesterday at $3.20, close to its 52-week low of $2.51.
“We note that approved irreversible pan-HER inhibitors have not shown meaningful clinical efficacy in TNBC. These newly published preclinical data have demonstrated that varlitinib is able to inhibit migration, invasion and mammosphere formation in TNBC cells, and therefore, has the potential to deliver clinically meaningful efficacy. Reversible inhibitors could also have a better safety profile than irreversible drugs. We believe ASLAN could seek a partner for further development of varlitinib in TNBC. In the wake of this update, we reiterate our Buy rating and $8.50 price target. Varlitinib showed positive efficacy in first-line BTC. Last week, ASLAN Pharmaceuticals reported positive preliminary data from the ongoing Phase 1b/2 trial of varlitinib + gemcitabine and cisplatin (gem/cis) in first-line biliary tract cancer (BTC).”
According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -16.6% and a 23.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on Aslan Pharmaceuticals Ltd is a Moderate Buy with an average price target of $8.50.
See today’s analyst top recommended stocks >>
In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Hold rating on Advaxis. The company’s shares closed yesterday at $0.31, close to its 52-week low of $0.18.
“We maintain our Neutral rating of ADXS with no price target due to the significant uncertainties surrounding the company’s core ADXS-HOT programs. (1) clinical; (2) financial; (3) regulatory; (4) commercial; and (5) intellectual property. For definitions and the distribution of analyst ratings, analyst certifications, and other disclosures, please refer to pages 2 – 3 of this report.Important Disclaimers This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c).”
According to TipRanks.com, Ramakanth is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -5.3% and a 30.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Collplant Holdings Ltd.
Currently, the analyst consensus on Advaxis is a Moderate Buy with an average price target of $3.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.